{
  "study_id": "NCT00311636",
  "study_title": "Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial",
  "table_name": "Table 1",
  "table_title": "Baseline Patient and Tumor Characteristics and Treatments Administered by Study Group",
  "footnotes": [
    "Percentages calculated on the total number of patients with hormone receptor-positive patients."
  ],
  "groups": [
    {
      "name": "Control Group",
      "n": 133,
      "type": "control"
    },
    {
      "name": "LHRHa Group",
      "n": 148,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, median (range), y",
      "standardized_name": "age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "numeric_median_iqr",
          "median": 39.0,
          "iqr_min": 25.0,
          "iqr_max": 45.0,
          "raw_string": "39 (25-45)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "numeric_median_iqr",
          "median": 39.0,
          "iqr_min": 24.0,
          "iqr_max": 45.0,
          "raw_string": "39 (24-45)"
        }
      ]
    },
    {
      "original_label": "Age distribution, y",
      "standardized_name": "age",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Age distribution, y"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Age distribution, y"
        }
      ]
    },
    {
      "original_label": "<30",
      "standardized_name": "age_less_than_30",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.8,
          "raw_string": "5 (3.8)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 5.4,
          "raw_string": "8 (5.4)"
        }
      ]
    },
    {
      "original_label": "30-34",
      "standardized_name": "age_30_to_34",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 17.3,
          "raw_string": "23 (17.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 15.5,
          "raw_string": "23 (15.5)"
        }
      ]
    },
    {
      "original_label": "35-39",
      "standardized_name": "age_35_to_39",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 33.8,
          "raw_string": "45 (33.8)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 31.1,
          "raw_string": "46 (31.1)"
        }
      ]
    },
    {
      "original_label": "40-44",
      "standardized_name": "age_40_to_44",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 57.0,
          "percentage": 42.9,
          "raw_string": "57 (42.9)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 44.6,
          "raw_string": "66 (44.6)"
        }
      ]
    },
    {
      "original_label": "45-49",
      "standardized_name": "age_45_to_49",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.3,
          "raw_string": "3 (2.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.4,
          "raw_string": "5 (3.4)"
        }
      ]
    },
    {
      "original_label": "Full-term pregnancies before breast cancer diagnosis, No.",
      "standardized_name": "prior_full_term_pregnancies",
      "category": "Medical History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Full-term pregnancies before breast cancer diagnosis, No."
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Full-term pregnancies before breast cancer diagnosis, No."
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "prior_full_term_pregnancies_0",
      "category": "Medical History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "prior_full_term_pregnancies",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 38.3,
          "raw_string": "51 (38.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 33.1,
          "raw_string": "49 (33.1)"
        }
      ]
    },
    {
      "original_label": "≥1",
      "standardized_name": "prior_full_term_pregnancies_1_or_more",
      "category": "Medical History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "prior_full_term_pregnancies",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 58.6,
          "raw_string": "78 (58.6)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 64.9,
          "raw_string": "96 (64.9)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "prior_full_term_pregnancies_unknown",
      "category": "Medical History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "prior_full_term_pregnancies",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.0,
          "raw_string": "4 (3.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2.0)"
        }
      ]
    },
    {
      "original_label": "Tumor size (T)",
      "standardized_name": "tumor_size",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Tumor size (T)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Tumor size (T)"
        }
      ]
    },
    {
      "original_label": "pT1",
      "standardized_name": "tumor_size_pt1",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_size",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 75.0,
          "percentage": 56.4,
          "raw_string": "75 (56.4)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 90.0,
          "percentage": 60.8,
          "raw_string": "90 (60.8)"
        }
      ]
    },
    {
      "original_label": "pT2",
      "standardized_name": "tumor_size_pt2",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_size",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 38.3,
          "raw_string": "51 (38.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 34.5,
          "raw_string": "51 (34.5)"
        }
      ]
    },
    {
      "original_label": "pT3-4",
      "standardized_name": "tumor_size_pt3_4",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_size",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.3,
          "raw_string": "3 (2.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.4,
          "raw_string": "5 (3.4)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "tumor_size_unknown",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_size",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.0,
          "raw_string": "4 (3.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.4,
          "raw_string": "2 (1.4)"
        }
      ]
    },
    {
      "original_label": "Axillary nodes (N)",
      "standardized_name": "axillary_nodes",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Axillary nodes (N)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Axillary nodes (N)"
        }
      ]
    },
    {
      "original_label": "pN0",
      "standardized_name": "axillary_nodes_pn0",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "axillary_nodes",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 50.4,
          "raw_string": "67 (50.4)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 41.2,
          "raw_string": "61 (41.2)"
        }
      ]
    },
    {
      "original_label": "pN1",
      "standardized_name": "axillary_nodes_pn1",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "axillary_nodes",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 33.1,
          "raw_string": "44 (33.1)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 58.0,
          "percentage": 39.2,
          "raw_string": "58 (39.2)"
        }
      ]
    },
    {
      "original_label": "pN2",
      "standardized_name": "axillary_nodes_pn2",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "axillary_nodes",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 13.5,
          "raw_string": "18 (13.5)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 18.2,
          "raw_string": "27 (18.2)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "axillary_nodes_unknown",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "axillary_nodes",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.0,
          "raw_string": "4 (3.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.4,
          "raw_string": "2 (1.4)"
        }
      ]
    },
    {
      "original_label": "Tumor grade (G)",
      "standardized_name": "tumor_grade",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Tumor grade (G)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Tumor grade (G)"
        }
      ]
    },
    {
      "original_label": "G1",
      "standardized_name": "tumor_grade_g1",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_grade",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.8,
          "raw_string": "5 (3.8)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 10.1,
          "raw_string": "15 (10.1)"
        }
      ]
    },
    {
      "original_label": "G2",
      "standardized_name": "tumor_grade_g2",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_grade",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 57.0,
          "percentage": 42.9,
          "raw_string": "57 (42.9)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 50.0,
          "percentage": 33.8,
          "raw_string": "50 (33.8)"
        }
      ]
    },
    {
      "original_label": "G3",
      "standardized_name": "tumor_grade_g3",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_grade",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 45.1,
          "raw_string": "60 (45.1)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 73.0,
          "percentage": 49.3,
          "raw_string": "73 (49.3)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "tumor_grade_unknown",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "tumor_grade",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 8.3,
          "raw_string": "11 (8.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.8,
          "raw_string": "10 (6.8)"
        }
      ]
    },
    {
      "original_label": "ER-positive, PR-positive, or both",
      "standardized_name": "hormone_receptor_positive",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 82.0,
          "raw_string": "109 (82.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 79.1,
          "raw_string": "117 (79.1)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "hormone_receptor_status_unknown",
      "category": "Tumor Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.5,
          "raw_string": "2 (1.5)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.4,
          "raw_string": "2 (1.4)"
        }
      ]
    },
    {
      "original_label": "Timing of chemotherapy",
      "standardized_name": "chemotherapy_timing",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Timing of chemotherapy"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Timing of chemotherapy"
        }
      ]
    },
    {
      "original_label": "Adjuvant therapy",
      "standardized_name": "adjuvant_therapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_timing",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 88.0,
          "raw_string": "117 (88.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 133.0,
          "percentage": 89.9,
          "raw_string": "133 (89.9)"
        }
      ]
    },
    {
      "original_label": "Neoadjuvant therapy",
      "standardized_name": "neoadjuvant_therapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_timing",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 7.5,
          "raw_string": "10 (7.5)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 8.8,
          "raw_string": "13 (8.8)"
        }
      ]
    },
    {
      "original_label": "Not begun",
      "standardized_name": "not_begun",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_timing",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.5,
          "raw_string": "6 (4.5)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.4,
          "raw_string": "2 (1.4)"
        }
      ]
    },
    {
      "original_label": "Type of chemotherapy",
      "standardized_name": "chemotherapy_type",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Type of chemotherapy"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Type of chemotherapy"
        }
      ]
    },
    {
      "original_label": "Anthracycline-based",
      "standardized_name": "anthracycline_based_chemotherapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 57.0,
          "percentage": 42.9,
          "raw_string": "57 (42.9)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 37.8,
          "raw_string": "56 (37.8)"
        }
      ]
    },
    {
      "original_label": "Anthracycline- and taxane-based",
      "standardized_name": "anthracycline_and_taxane_based_chemotherapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 46.6,
          "raw_string": "62 (46.6)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 86.0,
          "percentage": 58.1,
          "raw_string": "86 (58.1)"
        }
      ]
    },
    {
      "original_label": "CMF-based",
      "standardized_name": "cmf_based_chemotherapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "chemotherapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 6.0,
          "raw_string": "8 (6.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.7,
          "raw_string": "4 (2.7)"
        }
      ]
    },
    {
      "original_label": "Cumulative cyclophosphamide dose, median (IQR), mg/m²",
      "standardized_name": "cumulative_cyclophosphamide_dose",
      "unit": "mg/m²",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "numeric_median_iqr",
          "median": 4008.0,
          "iqr_min": 3624.0,
          "iqr_max": 5550.0,
          "raw_string": "4008 (3624-5550)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "numeric_median_iqr",
          "median": 4080.0,
          "iqr_min": 3697.0,
          "iqr_max": 5400.0,
          "raw_string": "4080 (3697-5400)"
        }
      ]
    },
    {
      "original_label": "Duration of chemotherapy, median (IQR), wk",
      "standardized_name": "chemotherapy_duration",
      "unit": "weeks",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "numeric_median_iqr",
          "median": 16.9,
          "iqr_min": 15.0,
          "iqr_max": 21.3,
          "raw_string": "16.9 (15.0-21.3)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "numeric_median_iqr",
          "median": 17.8,
          "iqr_min": 15.0,
          "iqr_max": 21.3,
          "raw_string": "17.8 (15.0-21.3)"
        }
      ]
    },
    {
      "original_label": "Treatment completed as planned",
      "standardized_name": "treatment_completion_status",
      "category": "Treatment Adherence",
      "time_point": "End of treatment",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Treatment completed as planned"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Treatment completed as planned"
        }
      ]
    },
    {
      "original_label": "Chemotherapy",
      "standardized_name": "chemotherapy_completed_as_planned",
      "category": "Treatment Adherence",
      "time_point": "End of treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "treatment_completion_status",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 121.0,
          "percentage": 91.0,
          "raw_string": "121 (91.0)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 143.0,
          "percentage": 96.6,
          "raw_string": "143 (96.6)"
        }
      ]
    },
    {
      "original_label": "LHRHa during chemotherapy",
      "standardized_name": "lhrha_completed_as_planned",
      "category": "Treatment Adherence",
      "time_point": "End of treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "treatment_completion_status",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "text",
          "text_value": "NA",
          "raw_string": "NA"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 142.0,
          "percentage": 95.9,
          "raw_string": "142 (95.9)"
        }
      ]
    },
    {
      "original_label": "Type of adjuvant endocrine therapy in hormone receptor-positive patients",
      "standardized_name": "adjuvant_endocrine_therapy_type",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "header",
          "raw_string": "Type of adjuvant endocrine therapy in hormone receptor-positive patientsa",
          "notes": "Percentages calculated on n=109 patients with hormone receptor-positive disease."
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "header",
          "raw_string": "Type of adjuvant endocrine therapy in hormone receptor-positive patientsa",
          "notes": "Percentages calculated on n=117 patients with hormone receptor-positive disease."
        }
      ]
    },
    {
      "original_label": "No treatment",
      "standardized_name": "no_adjuvant_endocrine_therapy",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 5.5,
          "raw_string": "6 (5.5)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 8.6,
          "raw_string": "10 (8.6)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "LHRHa alone",
      "standardized_name": "lhrha_alone",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.8,
          "raw_string": "3 (2.8)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.4,
          "raw_string": "4 (3.4)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "LHRHa + tamoxifen",
      "standardized_name": "lhrha_plus_tamoxifen",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 59.6,
          "raw_string": "65 (59.6)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 55.6,
          "raw_string": "65 (55.6)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "LHRHa + aromatase inhibitor",
      "standardized_name": "lhrha_plus_aromatase_inhibitor",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 10.1,
          "raw_string": "11 (10.1)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 8.6,
          "raw_string": "10 (8.6)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "Tamoxifen",
      "standardized_name": "tamoxifen_alone",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 20.2,
          "raw_string": "22 (20.2)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 23.9,
          "raw_string": "28 (23.9)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "Tamoxifen followed by aromatase inhibitor",
      "standardized_name": "tamoxifen_followed_by_aromatase_inhibitor",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "adjuvant_endocrine_therapy_type",
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.8,
          "raw_string": "2 (1.8)",
          "n_for_value": 109
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)",
          "n_for_value": 117
        }
      ]
    },
    {
      "original_label": "Duration of endocrine therapy, median (IQR), y",
      "standardized_name": "endocrine_therapy_duration",
      "unit": "years",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "numeric_median_iqr",
          "median": 5.0,
          "iqr_min": 4.78,
          "iqr_max": 5.03,
          "raw_string": "5.00 (4.78-5.03)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "numeric_median_iqr",
          "median": 5.0,
          "iqr_min": 4.96,
          "iqr_max": 5.1,
          "raw_string": "5.00 (4.96-5.10)"
        }
      ]
    },
    {
      "original_label": "Duration of adjuvant LHRHa, median (IQR), y",
      "standardized_name": "adjuvant_lhrha_duration",
      "unit": "years",
      "category": "Treatment Details",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Control Group",
          "data_type": "numeric_median_iqr",
          "median": 4.1,
          "iqr_min": 2.08,
          "iqr_max": 5.04,
          "raw_string": "4.10 (2.08-5.04)"
        },
        {
          "group_name": "LHRHa Group",
          "data_type": "numeric_median_iqr",
          "median": 4.08,
          "iqr_min": 2.06,
          "iqr_max": 4.92,
          "raw_string": "4.08 (2.06-4.92)"
        }
      ]
    }
  ]
}